Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/33268
Title: | Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest | Other Titles: | Lugar de acceso y tipo de anticoagulante en pacientes con sÃndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria | Authors: | Gargiulo, Giuseppe Valgimigli, Marco Sunnaker, Mikael VRANCKX, Pascal Frigoli, Enrico Leonardi, Sergio Spirito, Alessandro Gragnano, Felice Manavifar, Negar Galea, Roberto De Caterina, Alberto R. Calabro, Paolo Esposito, Giovanni Windecker, Stephan Hunziker, Lukas |
Issue Date: | 2020 | Publisher: | EDICIONES DOYMA S A | Source: | REVISTA ESPANOLA DE CARDIOLOGIA, 73 (11) , p. 893 -901 | Abstract: | Introduction and objectives: Patients who are vulnerable to hemodynamic or electrical disorders (VP) are often excluded from clinical trials and data on the optimal access-site or antithrombotic treatment are limited. We assessed outcomes of transradial vs transfemoral access and bivalirudin vs unfractionated heparin (UFH) in VP with acute coronary syndrome undergoing invasive management.Methods: The MATRIX trial randomized 8404 patients to radial or femoral access and 7213 patients to bivalirudin or UFH. Among them, 934 (11.1%) were deemed VP due to advanced Killip class (n = 808), cardiac arrest (n = 168), or both (n = 42). The 30-day coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE: death, myocardial infarction, or stroke) and net adverse clinical events (NACE: MACE or major bleeding).Results: MACE and NACE were similarly reduced with radial vs femoral access in VP and non-VP. Transradial access was also associated with consistent relative benefits in all-cause and cardiovascular mortality or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding with greater absolute benefits in VP. The effects of bivalirudin vs UFH on MACE and NACE were consistent in VP and non-VP. Bivalirudin was associated with lower all-cause and cardiovascular mortality in VP but not in non-VP, with borderline interaction testing. Bivalirudin reduced bleeding in both VP and non-VP with a larger absolute benefit in VP.Conclusions: In acute coronary syndrome patients undergoing invasive management, the effects of randomized treatments were consistent in VP and non-VP, but absolute risk reduction with radial access and bivalirudin were greater in VP, with a 5- to 10-fold lower number needed to treat for benefits. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. | Notes: | Valgimigli, M (corresponding author), Bern Univ Hosp, Dept Cardiol, CH-3010 Berna, Switzerland. marco.valgimigli@insel.ch |
Other: | Valgimigli, M (corresponding author), Bern Univ Hosp, Dept Cardiol, CH-3010 Berna, Switzerland. marco.valgimigli@insel.ch | Keywords: | Acute coronary syndrome;Radial access;Bivalirudin;Vulnerable patients;Acute heart failure;Cardiac arrest | Document URI: | http://hdl.handle.net/1942/33268 | ISSN: | 0300-8932 | e-ISSN: | 1579-2242 | DOI: | 10.1016/j.recesp.2020.01.012 | ISI #: | WOS:000585706300007 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
author version.pdf | Peer-reviewed author version | 1.01 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
8
checked on Aug 29, 2024
Page view(s)
36
checked on Jul 20, 2022
Download(s)
34
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.